Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837897 | 0.91 | TRPM2 (0.41) | TRPM2ADK | |
| SCHEMBL20711180 | 0.81 | TRPM2 (0.56) | TRPM2 | |
| SCHEMBL20711365 | 0.81 | TRPM2 (0.64) | TRPM2 | |
| SCHEMBL22837884 | 0.78 | GMPS (0.34) | — | |
| SCHEMBL22837903 | 0.77 | TRPM2 (0.46) | TRPM2 | |
| SCHEMBL20711311 | 0.77 | TRPM2 (0.51) | TRPM2 | |
| SCHEMBL22837885 | 0.77 | TRPM2 (0.36) | TRPM2 | |
| SCHEMBL23025515 | 0.73 | ADORA3 (0.53) | — | |
| SCHEMBL21311216 | 0.73 | ADORA2A (0.47) | — | |
| SCHEMBL25521510 | 0.73 | ADORA3 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | TRPM2 2028/4885ADK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.